Comparing Cogent Biosciences (NASDAQ:COGT) & Cardiac Biotech Solutions (OTCMKTS:CBSC)

Cardiac Biotech Solutions (OTCMKTS:CBSC) and Cogent Biosciences (NASDAQ:COGT) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.

Risk & Volatility

Cardiac Biotech Solutions has a beta of 1.81, indicating that its stock price is 81% more volatile than the S&P 500. Comparatively, Cogent Biosciences has a beta of 0.34, indicating that its stock price is 66% less volatile than the S&P 500.

Valuation & Earnings

This table compares Cardiac Biotech Solutions and Cogent Biosciences”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiac Biotech Solutions	$150,000.00	34.09	N/A	N/A	N/A
Cogent Biosciences	N/A	N/A	-$328.94 million	($2.17)	-18.01

Cardiac Biotech Solutions has higher revenue and earnings than Cogent Biosciences.

Profitability

This table compares Cardiac Biotech Solutions and Cogent Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cardiac Biotech Solutions	N/A	N/A	N/A
Cogent Biosciences	N/A	-104.27%	-54.64%

Analyst Recommendations

This is a breakdown of current recommendations for Cardiac Biotech Solutions and Cogent Biosciences, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiac Biotech Solutions	0	0	0	0	0.00
Cogent Biosciences	1	2	8	2	2.85

Cogent Biosciences has a consensus price target of $45.90, suggesting a potential upside of 17.45%. Given Cogent Biosciences’ stronger consensus rating and higher possible upside, analysts clearly believe Cogent Biosciences is more favorable than Cardiac Biotech Solutions.

About Cardiac Biotech Solutions

CB Scientific, Inc., through its US and international subsidiaries, provides innovative products and services in the ambulatory non-invasive cardiac monitoring space. Our FDA and CE cleared EKG devices, interactive cloud-based acquisition software, and smartphone apps for both iOS and Android platforms, provide improved compliance for patients at risk of abnormal heart rhythms as well as more accurate information for physicians.

About Cogent Biosciences

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.